Study Metrics
Total Sample
1566
Treatment Group
237
Control Group
1329
Covariates
12
PICO Comparisons
2
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Jin |
| Publication Year: | 2022 |
| DOI: | https://doi.org/10.1016/j.joca.2022.06.005 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | University of New South Wales, University of Sydney, Southern Medical University, University of Tasmania |
| Funding: | Declared: Public |
| Funding Institutions: | XJ received salary support from an NHMRC Early Career Fellowship (1104600), and DJH received salary support an NHMRC Investigator Grant (1194737). There are no other funding sources for this study. |
Study Context
| Disease: | Osteoarthritis |
| Disease Category: | Rheumatology |
| Data Type: | Registry |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 5419.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Missing Data Method: | Complete case |
| Matching Method: | IPTW |
| Analysis Method: | Hierarchical linear mixed models |
| Estimand: | ITT |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | Sanghi et al |
| Target Trial DOI: | https://doi.org/10.1007/s11999-013-3201-6 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
Change in WOMAC function score at 24 months
Sanghi et al., McAlindon et al., Arden et al., Jin et al.
SMD
Efficacy
Population
Patients aged ≥45 years with symptomatic knee osteoarthritis (KOA)
Intervention
Daily vitamin D supplementation of 1,000 IU for at least 4 days/week in the past 30 days
Comparison
No vitamin D supplementation in the past 30 days
Outcome
Change in WOMAC function score at 24 months
RCT Result
-0.92
95% CI: [-1.32, -0.51]
vs
TTE Result
0.02
95% CI: [-0.11, 0.15]
Concordance Assessment
Confidence Interval Overlap:
No
CIs do not overlap
CIs do not overlap
Direction Agreement:
Different Direction
Different conclusions
Different conclusions
Change in WOMAC pain score at 24 months
Sanghi et al., McAlindon et al., Arden et al., Jin et al.
SMD
Efficacy
Population
Patients aged ≥45 years with symptomatic knee osteoarthritis (KOA)
Intervention
Daily vitamin D supplementation of 1,000 IU for at least 4 days/week in the past 30 days
Comparison
No vitamin D supplementation in the past 30 days
Outcome
Change in WOMAC pain score at 24 months
RCT Result
-0.39
95% CI: [-0.78, 0.00]
vs
TTE Result
0.08
95% CI: [-0.07, 0.23]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Different Direction
Different conclusions
Different conclusions
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Pfizer, Lilly, Novartis, Merck Serono, TLCBio, Kolon Tissuegene |
| Funding Source: | Declared: Public |
| Funding Institutions: | XJ received salary support from an NHMRC Early Career Fellowship (1104600), and DJH received salary support an NHMRC Investigator Grant (1194737). There are no other funding sources for this study. |